A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia-Reference-Cited by-同舟云学术

A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia

Published:2022-03-22 Issue:11 Volume:128 Page:2138-2147
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Chen Xiaoxia¹,Huang Junwei¹,Xu Na¹,Fan Zhiping¹,Nie Danian²,Huang Fen¹,Sun Qixin³,Zhang Xinyou⁴,Liang Xinquan⁵,Shi Pengcheng¹,Wang Zhixiang¹,Liu Hui¹,Xu Jun¹,Dai Min¹,Yu Guopan¹^ORCID,Zhang Yu¹,Sun Jing¹,Liu Qifa¹^ORCID,Xuan Li¹^ORCID

Affiliation:

1. Department of Hematology Nanfang HospitalSouthern Medical University Guangzhou China

2. Department of Hematology Sun Yat‐Sen Memorial HospitalSun Yat‐Sen University Guangzhou China

3. Department of Geriatrics, Hematology and Oncology Ward Guangzhou First People's Hospital, School of Medicine, South China University of Technology Guangzhou China

4. Department of Hematology Shenzhen People's Hospital Shenzhen China

5. Department of Hematology First People's Hospital of Chenzhou Chenzhou China

Funder

National Natural Science Foundation of China

Research and Development

Natural Science Foundation of Guangdong Province

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.34182